Antibe Therapeutics Company Profile (CVE:ATE)

About Antibe Therapeutics

Antibe Therapeutics logoAntibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. Its lead compound, ATB-346, combines hydrogen sulfide with naproxen, which is a non-steroidal anti-inflammatory drug (NSAID). The Company's other products include ATB-352, which is indicated for the treatment of severe acute pain, and ATB-340 is a Gastrointestinal (GI)-safe derivative of aspirin. The Company also offers regenerative medical devices, which include PentOS (CGX-283), CGX-227, CGX-443 and URIST (CGX-276), all of which target bone regeneration, and are indicated for oral and maxillofacial surgery.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: CVE
  • Symbol: ATE
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $N/A
  • 200 Day Moving Average: $N/A
  • 52-Week Range: C$0.10 - C$0.27
  • Trailing P/E Ratio: N/A
  • P/E Growth: N/A
  • Market Cap: $N/A
  • Outstanding Shares: 93,418,000
Additional Links:

Analyst Ratings

Consensus Ratings for Antibe Therapeutics (CVE:ATE) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Antibe Therapeutics (CVE:ATE)
Show:
DateFirmActionRatingPrice TargetDetails
3/13/2015M PartnersReiterated RatingBuyView Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Antibe Therapeutics (CVE:ATE)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Antibe Therapeutics (CVE:ATE)
Current Year EPS Consensus Estimate: $-0.10 EPS

Dividends

Dividend History for Antibe Therapeutics (CVE:ATE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Antibe Therapeutics (CVE:ATE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/29/2016Scott Wilson CurtisInsiderBuy19,500C$0.13C$2,535.00
3/28/2016Scott Wilson CurtisInsiderBuy30,500C$0.13C$3,965.00
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Antibe Therapeutics (CVE:ATE)
DateHeadline
businesswire.com logoAntibe Therapeutics Engages MKR Group for US Investor Relations - Business Wire (press release) (CVE:ATE)
www.businesswire.com - February 22 at 11:22 AM
finance.yahoo.com logoAntibe Therapeutics Engages MKR Group for U.S. Investor Relations (CVE:ATE)
finance.yahoo.com - February 21 at 9:46 AM
businesswire.com logoAntibe Therapeutics Announces the Launch of PentOS OI™ Max, Its Newest Bone Graft Substitute for Oral and ... - Business Wire (press release) (CVE:ATE)
www.businesswire.com - January 31 at 8:53 PM
finance.yahoo.com logoAntibe Therapeutics Announces the Launch of PentOS OI™ Max, Its Newest Bone Graft Substitute for Oral and Maxillofacial Surgery (CVE:ATE)
finance.yahoo.com - January 31 at 3:52 PM
News IconAntibe Therapeutics Inc ATE Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (CVE:ATE)
www.bioportfolio.com - January 21 at 3:38 PM
businesswire.com logoAntibe Therapeutics Announces Change of Auditor to Ernst & Young (CVE:ATE)
www.businesswire.com - January 19 at 2:19 AM
businesswire.com logoAntibe Therapeutics Completes Final Closing of Private Placement Bringing Total Proceeds to $2.7 Million (CVE:ATE)
www.businesswire.com - December 22 at 2:44 AM
businesswire.com logoAntibe Therapeutics Completes Final Closing of Private Placement Bringing Total Proceeds to $2.7 Million - Business Wire (press release) (CVE:ATE)
www.businesswire.com - December 21 at 9:44 PM
4-traders.com logoAntibe Therapeutics : Raises $2.4 Million in First Tranche of Private Placement (CVE:ATE)
www.4-traders.com - December 18 at 1:45 AM
businesswire.com logoAntibe Therapeutics Raises $2.4 Million in First Tranche of Private Placement - Business Wire (press release) (CVE:ATE)
www.businesswire.com - December 17 at 1:59 AM
businesswire.com logoAntibe Therapeutics Raises $2.4 Million in First Tranche of Private Placement (CVE:ATE)
www.businesswire.com - December 16 at 3:56 PM
News IconWhat The Charts Are Saying About Antibe Therapeutics Inc. (TSXV:ATE) - Stock Newsweek (CVE:ATE)
stocknewsweek.com - December 11 at 3:33 PM
News IconStock in Focus: Antibe Therapeutics Inc. (TSXV:ATE) - Stock Newsweek (CVE:ATE)
stocknewsweek.com - December 9 at 3:43 PM
News IconInvestor Monitor: Narrowing in on Antibe Therapeutics Inc. (TSXV:ATE) - Stock Newsweek (CVE:ATE)
stocknewsweek.com - December 6 at 3:54 PM
News IconLooking at the Numbers for Antibe Therapeutics Inc. (TSXV:ATE) - Stock Newsweek (CVE:ATE)
stocknewsweek.com - December 2 at 9:07 PM
News IconToday's Price Action: Antibe Therapeutics Inc (ATE) Soared 6.06% on Dec 2 - Herald KS (CVE:ATE)
heraldks.com - December 2 at 9:07 PM
stockhouse.com logoANTIBE THERAPEUTICS INC V.ATE (CVE:ATE)
www.stockhouse.com - December 1 at 3:43 PM
News IconResearch Reports Initiated on Healthcare Stocks OrganiGram Holdings, Aphria, Antibe Therapeutics, and biOasis ... - Trader Planet (CVE:ATE)
www.traderplanet.com - November 30 at 8:42 PM
News IconTechnical Buzz on Antibe Therapeutics Inc. (TSXV:ATE) - Stock Newsweek (CVE:ATE)
stocknewsweek.com - November 30 at 8:42 PM
businesswire.com logoAntibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results - Business Wire (press release) (CVE:ATE)
www.businesswire.com - November 30 at 8:42 PM
News IconAntibe Therapeutics, Inc. (ATBPF: OTCQX International) | Antibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results (CVE:ATE)
satprnews.com - November 30 at 9:21 AM
businesswire.com logoAntibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results (CVE:ATE)
www.businesswire.com - November 30 at 9:21 AM
baystreet.ca logoResearch Reports Initiated on Healthcare Stocks OrganiGram Holdings, Aphria, Antibe Therapeutics, and biOasis Technologies (CVE:ATE)
www.baystreet.ca - November 29 at 4:49 PM
News IconAntibe Therapeutics, Inc. ATE Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (CVE:ATE)
www.bioportfolio.com - November 22 at 1:42 PM
businesswire.com logoAntibe Therapeutics Confirms Non-Addictive Properties for Its Second Pipeline Drug, ATB-352, a Potent, Non-Addictive Pain-Killer (CVE:ATE)
www.businesswire.com - October 17 at 8:27 AM
businesswire.com logoAntibe Therapeutics Announces Launch of Strategic Growth Initiative in the U.S. Market for Dental Biologics (CVE:ATE)
www.businesswire.com - October 11 at 3:41 PM
stockhouse.com logoAntibe Therapeutics, Inc. V.ATE (CVE:ATE)
www.stockhouse.com - October 4 at 8:26 AM
News IconATB-346 Shows Promising Results in Experimental Melanoma (CVE:ATE)
www.enhancedonlinenews.com - September 23 at 8:39 AM
businesswire.com logoAntibe Therapeutics to Present at 2016 Rodman & Renshaw Global Investment Conference (CVE:ATE)
www.businesswire.com - September 7 at 12:34 PM
businesswire.com logoAntibe Therapeutics Reports Q1 2017 Interim Financial and Operating Results (CVE:ATE)
www.businesswire.com - August 30 at 3:37 PM
finance.yahoo.com logoAntibe Therapeutics Announces the Launch of Neomem® FlexPlus, a High-Performance Barrier Membrane for Oral Surgery (CVE:ATE)
finance.yahoo.com - August 16 at 3:41 PM
businesswire.com logoAntibe Therapeutics Announces Successful Phase 2 Trial of ATB-346 in Osteoarthritis (CVE:ATE)
www.businesswire.com - August 8 at 8:25 AM
finance.yahoo.com logoAntibe Therapeutics Reports 2016 Year-End Financial and Operating Results (CVE:ATE)
finance.yahoo.com - July 29 at 9:05 PM
businesswire.com logoAntibe Therapeutics Announces the Appointment of New Board Member and Provides Update on Phase 2 Trial of ATB-346 (CVE:ATE)
www.businesswire.com - July 19 at 9:49 AM
finance.yahoo.com logoAntibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $1,455,000 (CVE:ATE)
finance.yahoo.com - June 22 at 8:46 PM
streetinsider.com logoAntibe Therapeutics Raises $968,500 in First Tranche of Non-Brokered Private Placement (CVE:ATE)
www.streetinsider.com - June 10 at 9:28 PM
businesswire.com logoAntibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference (CVE:ATE)
www.businesswire.com - May 30 at 10:50 AM
thestreet.com logoAntibe Therapeutics To Present At 2016 Bloom Burton & Co. Healthcare Investor Conference (CVE:ATE)
www.thestreet.com - May 2 at 11:57 AM
stockhouse.com logoAntibe Therapeutics Announces the Launch of PentOS OI(TM) Putty, a High-Quality Bone Graft Substitute for Oral and Maxillofacial Surgery (CVE:ATE)
www.stockhouse.com - April 18 at 11:28 AM
businesswire.com logoAntibe Therapeutics Announces the Launch of PentOS OI™ Putty, a High-Quality Bone Graft Substitute for Oral and Maxillofacial Surgery (CVE:ATE)
www.businesswire.com - April 18 at 11:28 AM
thestreet.com logoAntibe Therapeutics Announces Grant Of Stock Options (CVE:ATE)
www.thestreet.com - March 10 at 10:03 AM
thestreet.com logoAntibe Therapeutics' ATB-346 Receives Approval For Phase 2 Clinical Trial In Osteoarthritis Patients (CVE:ATE)
www.thestreet.com - March 7 at 9:59 AM
businesswire.com logoAntibe Therapeutics Receives Approval to Proceed to Phase 2 Clinical Trial (CVE:ATE)
www.businesswire.com - March 5 at 9:38 AM
thestreet.com logoAntibe Therapeutics Reports Q3 2016 Interim Financial And Operating Results (CVE:ATE)
www.thestreet.com - February 29 at 9:58 PM
businesswire.com logoProfound Preventative and Restorative Effects of ATB-346 in Mice with Genetic Predisposition to Intestinal Cancer (CVE:ATE)
www.businesswire.com - February 25 at 9:36 AM
finance.yahoo.com logoAntibe Therapeutics Inc. (ATE.V) (CVE:ATE)
finance.yahoo.com - February 6 at 8:54 AM
thestreet.com logoAntibe Therapeutics Closes Acquisition Of Minority Interest In Citagenix Inc. (CVE:ATE)
www.thestreet.com - February 2 at 7:42 PM
finance.yahoo.com logoAntibe Therapeutics Announces Payment in Kind Election (CVE:ATE)
finance.yahoo.com - January 28 at 9:04 AM

Social

What is Antibe Therapeutics' stock symbol?

Antibe Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ATE."

How do I buy Antibe Therapeutics stock?

Shares of Antibe Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How much does a share of Antibe Therapeutics stock cost?

One share of Antibe Therapeutics stock can currently be purchased for approximately C$0.23.

Antibe Therapeutics (CVE:ATE) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Antibe Therapeutics (CVE:ATE)

Earnings History Chart

Earnings by Quarter for Antibe Therapeutics (CVE:ATE)

Dividend History Chart

Dividend Payments by Quarter for Antibe Therapeutics (CVE:ATE)

Last Updated on 2/24/2017 by MarketBeat.com Staff